Organon & Co. (NYSE:OGN) Receives Average Recommendation of “Reduce” from Analysts

by · The Cerbat Gem

Shares of Organon & Co. (NYSE:OGN – Get Free Report) have received a consensus rating of “Reduce” from the seven ratings firms that are covering the company, Marketbeat Ratings reports. Four investment analysts have rated the stock with a sell recommendation, two have given a hold recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $8.3750.

A number of research analysts recently weighed in on the stock. Wall Street Zen raised shares of Organon & Co. from a “hold” rating to a “buy” rating in a report on Saturday, January 3rd. Barclays began coverage on shares of Organon & Co. in a report on Tuesday, December 9th. They issued an “underweight” rating and a $7.50 target price on the stock. Morgan Stanley decreased their target price on shares of Organon & Co. from $10.00 to $9.00 and set an “equal weight” rating on the stock in a research report on Tuesday, November 11th. JPMorgan Chase & Co. reduced their price objective on Organon & Co. from $14.00 to $12.00 and set an “underweight” rating on the stock in a research note on Tuesday, November 11th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Organon & Co. in a research report on Wednesday, October 8th.

Check Out Our Latest Analysis on OGN

Organon & Co. Stock Down 1.3%

OGN opened at $8.03 on Friday. The company has a market capitalization of $2.09 billion, a PE ratio of 4.18, a price-to-earnings-growth ratio of 1.67 and a beta of 0.58. The firm has a 50-day simple moving average of $7.29 and a two-hundred day simple moving average of $8.83. The company has a quick ratio of 1.20, a current ratio of 1.75 and a debt-to-equity ratio of 9.69. Organon & Co. has a 52 week low of $6.18 and a 52 week high of $17.23.

Organon & Co. (NYSE:OGN – Get Free Report) last posted its earnings results on Monday, November 10th. The company reported $1.01 EPS for the quarter, topping analysts’ consensus estimates of $0.93 by $0.08. The company had revenue of $1.60 billion for the quarter, compared to the consensus estimate of $1.57 billion. Organon & Co. had a return on equity of 143.47% and a net margin of 7.95%.During the same period in the previous year, the business earned $1.38 earnings per share. Analysts forecast that Organon & Co. will post 3.68 earnings per share for the current fiscal year.

Organon & Co. Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, December 11th. Investors of record on Thursday, November 20th were given a $0.02 dividend. The ex-dividend date was Thursday, November 20th. This represents a $0.08 dividend on an annualized basis and a yield of 1.0%. Organon & Co.’s dividend payout ratio (DPR) is currently 4.17%.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. GAMMA Investing LLC raised its stake in shares of Organon & Co. by 22.4% during the second quarter. GAMMA Investing LLC now owns 5,645 shares of the company’s stock valued at $55,000 after acquiring an additional 1,034 shares in the last quarter. Maryland State Retirement & Pension System raised its position in Organon & Co. by 1.4% during the 2nd quarter. Maryland State Retirement & Pension System now owns 88,420 shares of the company’s stock valued at $856,000 after purchasing an additional 1,195 shares in the last quarter. Rexford Capital Inc. lifted its holdings in shares of Organon & Co. by 14.9% in the 3rd quarter. Rexford Capital Inc. now owns 11,380 shares of the company’s stock worth $122,000 after buying an additional 1,480 shares during the period. Amalgamated Bank lifted its holdings in shares of Organon & Co. by 1.9% in the 3rd quarter. Amalgamated Bank now owns 79,805 shares of the company’s stock worth $852,000 after buying an additional 1,514 shares during the period. Finally, Integrated Wealth Concepts LLC grew its position in shares of Organon & Co. by 2.8% during the 3rd quarter. Integrated Wealth Concepts LLC now owns 58,648 shares of the company’s stock worth $626,000 after buying an additional 1,594 shares in the last quarter. Institutional investors own 77.43% of the company’s stock.

About Organon & Co.

(Get Free Report)

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.

Further Reading